安络化纤丸治疗慢性乙型肝炎肝纤维化临床观察

Clinical Observation of "Anluo Huaxian Pill" in Treating Hepatic Fibrosis Following Chronic Hepatitis B

目的观察安络化纤丸治疗慢性乙型肝炎肝纤维化的临床疗效。方法将134例患者分为两组,治疗组70例服用安络化纤丸;对照组64例口服护肝宁片、复方甘草酸苷片。两组疗程均为3个月。结果治疗组可有效改善慢性乙型肝炎患者临床症状与体征,恢复肝功能,血清透明质酸均值和异常率均下降(P<0.01);对照组变化不明显,组间比较(P<0.01);两组血清层黏连蛋白在治疗前后均值和异常率变化不明显;两组血清Ⅲ型前胶原治疗后均值和异常率均下降(P<0.05,P<0.01),组间比较无显著性差异;两组血清Ⅳ型胶原均值在治疗后均下降(P<0.01);治疗组下降幅度比对照组明显(P<0.01),异常率的下降治疗组作用明显(P<0.01)略好于对照组(P<0.05)。结论安络化纤丸具有保肝作用,能阻止慢性乙型肝炎肝纤维化的进展。

Objective To observe the clinical efficacy of ＂Anluo Huaxian Pill＂ in the treatment of hepatic fibrosis following chronic hepatitis B. Methods 134 subjects were randomized into two groups： treatment group in which 70 cases were treated with ＂Anluo Huaxian Pill＂ and control group in which 64 cases were treated with ＂Huganning Tablet＂ and ＂Compound Glycyn＇hizin Tablet＂, both with a course of three months. Results In the treatment group, clinical symptoms and signs and liver functions were obviously improved, and the contents and abnormality rate of hyaluronic acid（HA） were reduced（ P 〈0.01 ） , while in the control group, these changes were insignificant, but with striking differences between the two groups（P 〈0.01 ）. After treatment, the contents and abnormality rate of collagen Ⅲ were decreased in both groups（ P 〈0.01, P 〈0.05 ）, with no difference between the two groups ; the contents and abnormality rate of collagen Ⅳ were decreased in both groups（P 〈0.01, P 〈0.05） , with more decrease in the treatment group than in the control group（P 〈0.01 , P 〈0.05）. Conclusion ＂Anluo Huaxian Pill＂ is effective to protect the liver and prevent the progress of hepatic fibrosis following chronic hepatitis B.